Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol
- PMID: 8173686
Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol
Abstract
A new, once-daily combination tablet containing felodipine and metoprolol has been developed, using extended-release techniques to obtain even plasma concentrations throughout the dosing interval. The tablet consists of a hydrophilic matrix containing felodipine in which many small membrane-coated metoprolol pellets are embedded. On contact with gastrointestinal fluids, felodipine is released at an almost constant rate by erosion of the hydrophilic matrix. The release of metoprolol also follows near zero-order kinetics, and is mainly controlled by diffusion through the membrane covering each individual metoprolol bead. Smooth plasma concentration profiles are obtained for both drugs of the combination, similar to those found with the corresponding single-drug formulations: felodipine extended-release tablets and metoprolol controlled-release tablets. The new fixed combination tablet also consistently provides even plasma concentrations of felodipine and metoprolol after administration together with food and in elderly hypertensive patients. The convenience of one tablet per day for effective antihypertensive treatment with a combination of felodipine and metoprolol should improve patient compliance with the prescribed regimen.
Similar articles
-
Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. The German Multicentre Study Group.Blood Press Suppl. 1993;1:30-6. Blood Press Suppl. 1993. PMID: 8173688 Clinical Trial.
-
Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.Blood Press Suppl. 1993;1:16-21. Blood Press Suppl. 1993. PMID: 7909705 Clinical Trial.
-
Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group.Blood Press Suppl. 1993;1:22-9. Blood Press Suppl. 1993. PMID: 8173687 Clinical Trial.
-
Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs--the rationale and benefits of combining felodipine and metoprolol.J Hum Hypertens. 1995 Jul;9 Suppl 2:S37-42. J Hum Hypertens. 1995. PMID: 7562898 Review.
-
A felodipine-metoprolol extended-release tablet: its properties and clinical development.J Hum Hypertens. 1995 Jul;9 Suppl 2:S43-7. J Hum Hypertens. 1995. PMID: 7562899 Review.
Cited by
-
Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.Drugs. 1995 Sep;50(3):454-64. doi: 10.2165/00003495-199550030-00004. Drugs. 1995. PMID: 8521768 Review.
-
Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.Drugs. 2000 Jan;59(1):141-57. doi: 10.2165/00003495-200059010-00011. Drugs. 2000. PMID: 10718104 Review.